Simultaneous determination of leflunomide and its active metabolite, a77 1726, in human plasma by high-performance liquid chromatography

Biomedical Chromatography

Volumn 17, Issue 4, 2003, Pages 276-281

  Schmidt, Andreas ^a   Schwind, Bianca ^a   Gillich, Martin ^a   Brune, Kay ^a   Hinz, Burkhard ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Isoxazol derivative; Metabolism; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

DISEASES; METABOLITES; PATIENT TREATMENT; PLASMA (HUMAN);

5-METHYLISOXAZOLE; ACTIVE METABOLITES; CARBOXAMIDES; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN PLASMAS; ISOXAZOL DERIVATIVE; LEFLUNOMIDE; RHEUMATOID ARTHRITIS; SIMULTANEOUS DETERMINATIONS; UV DETECTION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACETONITRILE; DRUG METABOLITE; FACHINFORMATION ARAVA; FORMIC ACID; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; PYRIMIDINE; TERIFLUNOMIDE; WARFARIN; WATER;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG RETENTION; ELECTROPHORETIC MOBILITY; FLOW RATE; HUMAN; LIQUID LIQUID EXTRACTION; PYRIMIDINE SYNTHESIS; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RHEUMATOID ARTHRITIS; SEPARATION TECHNIQUE; STANDARD; STEADY STATE; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 0038048455     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.244     Document Type: Article

References (16)

1. Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rude E, Thoenes GH, Kuchle CC, Schorlemmer HU, Bremer E, Finnegan A and Schleyerbach R. Leflunomide (HWA 486), a novel immunomodulating compound for treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents and Actions 1991; 32: 10-21.
2. Bartlett RR, Campion P, Musikic P, Schleyerbach R, Zielinski T and Schorlemmer HU. Nonsteroidal Anti-inflammatory Drugs: Mechanisms and Clinical Uses, Lewis AJ, Furst DE (eds). Marcel Dekker: New York, 1994; 349-366.
3. Bartlett RR, Brendel S, Zielinski T and Schorlemmer HU. Lefunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplantation Proceedings 1996; 28: 3074-3078.
4. Beaman JM, Hackett LP, Luxton G and Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. Annals of Pharmacotherapy 2002; 36: 75-77.
5. Breedveld FC and Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Annals of Rheumatic Disease 2000; 59: 841-849.
6. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, Young JM, Nakano G and Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. Journal of Pharmacologv and Experimental Therapeutics 1995; 275: 1043-1049.
7. Chong AS, Finnegan A, Jiang X, Gebel H, Sankary HN, Foster P and Williams JW. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361-1366.
8. Davis JP, Cain GA, Pitts WJ, Magolda RL and Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996; 35: 1270-1273.
9. Dias VC, Lucien J, LeGatt DF and Yatscoff RW. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. Therapeutic Drug Monitoring 1995; 17: 84-88.
10. FDA. Study YU#204. Clinical pharmacology/biopharmaceutics review. Arava® Leflunomide tablets; summary basis of approval equivalent. FDA Summary Basis of Approval. NDA: 20-905, 1998.
11. Green S, Watanabe K, Braatz-Trulson J and Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochemical Pharmacology 1995; 50: 861-967.
12. Lucien J, Dias VC, LeGatt DF and Yatscoff RW. Blood distribution and single-dose pharmacokinetics of leflunomide. Therapeutic Drug Monitoring 1995; 17: 454-459.
13. Mattar T, Kochhar K, Bartlett RR, Bremer EG and Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Letters 1993; 334: 161-164.
14. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT and Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research 2000; 17: 1551-1557.
15. Silva HT Jr, Cao W, Shorthouse RA, Loffler M and Morris RE. In vitro and in vivo effects of leflunomide, brequinar and cyclosporine on pyrimidine biosynthesis. Transplantation Proceedings 1997; 29: 1292-1293.
16. Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW and Chong AS. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in Mrl/MpJ-Ipr/lpr mice. Journal of Immunology 1997; 159: 167-174.